| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More | Frank Vinluan | 08/23/19 | National |
| FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns | Ben Fidler | 08/19/19 | Boston |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More | Alex Lash | 05/03/19 | National |
| The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski | Ben Fidler | 03/11/19 | National |
| Bio Roundup: An Alzheimer’s Head-Scratcher, OUTBio, GSK & Gilead Shakeups | Ben Fidler | 07/27/18 | National |
| Nabriva Bolsters Antibiotics Pipeline with Zavante Acquisition | Frank Vinluan | 07/24/18 | San Diego |
| Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More | Ben Fidler | 09/22/17 | National |
